Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides

Antisense Nucleic Acid Drug Dev. Spring 1996;6(1):9-16. doi: 10.1089/oli.1.1996.6.9.


Overexpression of erbB-2 proto-oncogene has been found in 20%-30% of human breast carcinomas and in most cases correlates with poor clinical prognosis. Using antisense oligonucleotides targeted to the 5' cap region of erbB-2RNA, we were able to inhibit erbB-2 protein expression, proliferation, and anchorage-independent growth of breast cancer cells up to 90%. These effects were sequence specific and restricted to cells expressing elevated level of erbB-2 protein. These support the feasibility of using antisense erbB-2 oligonucleotides to inhibit the progression of erbB-2-overexpressing breast cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / toxicity*
  • Base Sequence
  • Biomarkers, Tumor
  • Blotting, Western
  • Breast Neoplasms
  • Cell Adhesion
  • Cell Division / drug effects
  • Cell Line
  • Female
  • Genes, erbB-2*
  • Humans
  • Oligonucleotides, Antisense / chemistry
  • Oligonucleotides, Antisense / toxicity*
  • Prognosis
  • Proto-Oncogene Mas
  • RNA Caps
  • Receptor, ErbB-2 / analysis*
  • Receptor, ErbB-2 / biosynthesis
  • Tumor Cells, Cultured


  • Antineoplastic Agents
  • Biomarkers, Tumor
  • MAS1 protein, human
  • Oligonucleotides, Antisense
  • Proto-Oncogene Mas
  • RNA Caps
  • Receptor, ErbB-2